Literature DB >> 6694918

Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3.

B Hartley-Asp.   

Abstract

In growth proliferation experiments on two human prostatic carcinoma cell lines, DU 145 cells were found to be more sensitive to the cytotoxic effect of estramustine and nor-nitrogen mustard than PC-3 cells. Estramustine was, however, much more cytotoxic in both cell lines than nor-nitrogen mustard. Cytogenetic experiments revealed that estramustine produced a drastic increase of the mitotic index in both these cell lines. This increase could be accounted for by the arrest of cells in their first treatment-metaphase. The arrested metaphases exhibited all the characteristics commonly found for stathmokinetic agents such as colchicine and vinca-analogues. No mitotic arrest was found for nor-nitrogen mustard but chromosomal aberrations were found at toxic concentrations. Estradiol exhibited minimal toxicity and caused no mitotic arrest in these cell lines. The mitotic arrest induced by estramustine was found to be reversible on removal of the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6694918     DOI: 10.1002/pros.2990050109

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

1.  Presence of oestrogen receptors on target cells and antiproliferative activity of estramustine phosphate: positive correlation for human tumours in vitro.

Authors:  J Pavelić; I Zgradić; K Pavelić
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine.

Authors:  K D Tew; M E Stearns
Journal:  Urol Res       Date:  1987

3.  Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.

Authors:  D Panda; H P Miller; K Islam; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

4.  Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study.

Authors:  D Yoshida; S Hoshino; T Shimura; H Takahashi; A Teramoto
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

Review 5.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

6.  Estramustine phosphate reversibly inhibits an early stage during adenovirus replication.

Authors:  E Everitt; H Ekstrand; B Boberg; B Hartley-Asp
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.

Authors:  Daisaku Hirano; Yusuke Nagane; Katsuhiko Satoh; Junichi Mochida; Shuji Sugimoto; Taketo Ichinose; Satoru Takahashi; Toshiya Maebayashi; Tsutomu Saitoh
Journal:  Int Urol Nephrol       Date:  2009-05-16       Impact factor: 2.370

8.  Impairment of estramustine phosphate absorption by concurrent intake of milk and food.

Authors:  P O Gunnarsson; T Davidsson; S B Andersson; C Backman; S A Johansson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 9.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

10.  Accumulation of estramustine and estromustine in adipose tissue of rats and humans.

Authors:  P O Gunnarsson; S B Andersson; A A Sandberg; M Ellman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.